by Intranasal drug delivery devices help administer drugs directly into the nasal cavity for local or systemic treatment of conditions like allergies, migraine, pain etc. These devices provide non-invasive delivery with advantages like rapid drug absorption, improved bioavailability and bypass of first-pass liver metabolism. The nasal cavity has a large epithelial surface area and rich vasculature allowing for efficient drug absorption. Growing prevalence of conditions needing nasal drug administration and improved patient compliance with easy self-administration are driving demand for intranasal devices.
The global Intranasal Drug Delivery Devices market is estimated to be valued at US$ 3.27 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Intranasal Drug Delivery Devices are GlaxoSmithKline PLC, AstraZeneca PLC, Pfizer, Inc., OptiNose, Inc., 3M Company, Becton, Dickinson and Company, Promius Pharma, LLC, Cadila Pharmaceuticals Ltd., B.F. Ascher & Company, Inc., PendoPharm, Inc., Douglas Pharmaceuticals Ltd., ENT Technologies Pty. Ltd., NAVEH Pharma Ltd., Novartis AG, Neurelis, Inc., Aptargroup, Inc.
Growing demand – The Intranasal Drug Delivery Devices market Demand is anticipated to grow owing to the increasing prevalence of allergies, migraine, and other conditions requiring self-administration of drugs. Intranasal administration is gaining popularity for systemic drug delivery to avoid first-pass liver metabolism.
Global expansion – Major players are investing in R&D and new product development to expand globally. Partnerships with contract manufacturing organizations and regional players aid international market penetration in high growth regions.
Market key trends
Devices enabling multi-dose administration with improved accuracy and precision are a key trend. Self-administrable devices with user-friendly designs are gaining traction. Adaptive delivery technologies allowing adjustable dosing based on disease severity are being researched to improve outcomes. Development of stable dosage forms and delivery of novel biologics via the nasal route presents opportunities.
Porter’s Analysis
Threat of new entrants: Low cost of production and well established brand names lower the threat of new entrants.
Bargaining power of buyers: Large customer base results in low bargaining power of individual buyers.
Bargaining power of suppliers: Established suppliers and availability of substitute materials controls supplier power.
Threat of new substitutes: Limited substitutes exist due to unique drug delivery through nasal route.
Competitive rivalry: Intense competition exists between major players to gain higher market share.
Geographical Regions
North America holds the largest share in Intranasal Drug Delivery Devices Market Regional Analysis due to increasing prevalence of chronic diseases and technological advancements. The United States represents the majority share due to high adoption of innovative drug delivery technologies.
Asia Pacific region is expected to witness the fastest growth over the forecast period owing to rising healthcare expenditure, growing geriatric population and increasing cases of respiratory disorders. Expanding pharmaceutical industry in emerging nations like India and China will further aid the market expansion.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
